Dentist-reported organoleptic test (OLT) score (scale 0 to 5) · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
It is very uncertain whether halita mouthrinse changes dentist-reported organoleptic test (OLT) score (scale 0 to 5) compared with perio-plus mouthrinse (very low certainty).
1 finding from 1 review
Patient's family member-reported VAS score (scale 0 to 100) · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1000 mg champignon extract showed no clear difference in patient's family member-reported VAS score (scale 0 to 100) compared with 50 mg champignon extract; GRADE not reported.
1 finding from 1 review
Volatile sulphur compounds (VSC), halimeter · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
Herbal mouthwash led to lower volatile sulphur compounds (VSC) compared with placebo mouthwash; GRADE not reported.
1 finding from 1 review
OLT, VSC and patient satisfaction scores · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Wilhelm 2012 (3-arm cross-over trial) compared toothbrushing with a reference toothpaste, with reference toothpaste plus tongue cleaning, and toothbrushing plus tongue cleaning with a tooth-and-tongue gel (OLT, VSC,…
1 study
GRADE not reported
Normalcy of diet (mean worst ability to eat, 1 to 4 scale) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (mean worst ability to eat, 1 to 4 scale) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in xerostomia (dry mouth, yes/no) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Interruptions to cancer treatment (radiotherapy interruptions) · Adults with cancer receiving treatment
Granulocyte-colony stimulating factor (G-CSF) showed no clear difference in interruptions to cancer treatment (radiotherapy interruptions) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in interruptions to cancer treatment compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in progression-free survival compared with placebo; GRADE not reported.
1 finding from 1 review
HR 1.06 [0.80, 1.42]
3 studies
GRADE not reported
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in overall survival compared with artificial saliva; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Dysphagia (grade >= 3, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in dysphagia (grade >= 3, 0-4 scale) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to GM-CSF typically bone pain, nausea, fever and headache; not reported as serious; reporting poor and inconsistent (SoF comments cell, not GRADE-rated)
8 studies
GRADE not reported
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
4 findings from 1 review
RR 0.96 [0.88, 1.05]
4 studies · 655 participants
GRADE not reported
Two studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented
2 studies
GRADE not reported
RR 0.95 [0.90, 1.00]
2 studies · 374 participants
GRADE not reported
Show 1 more finding
Oral mucositis (any severity) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (any severity) compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review